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Epicardial adipose tissue (EAT) has the unique property to release mediators that nourish the heart in healthy conditions, an effect
that becomes detrimental when volume expands and proinflammatory cytokines start to be produced. Proprotein convertase
subtilisin/kexin type 9 (PCSK9), a proinflammatory mediator involved in atherosclerosis, is also produced by visceral fat. Due to
the correlation of inflammation with PCSK9 and EAT enlargement, we evaluated whether PCSK9 was expressed in EAT and
associated with EAT inflammation and volume. EAT samples were isolated during surgery. EAT thickness was measured by
echocardiography. A microarray was used to explore EAT transcriptoma. The PCSK9 protein levels were measured by Western
Blot in EAT and ELISA in plasma. PCSK9 was expressed at both the gene and protein levels in EAT. We found a positive
association with EAT thickness and local proinflammatory mediators, in particular, chemokines for monocytes and lymphocytes.
No association was found with the circulating PCSK9 level. The expression of PCSK9 in EAT argues that PCSK9 is part of the
EAT secretome and EAT inflammation is associated with local PCSK9 expression, regardless of circulating PCSK9 levels.
Whether reducing EAT inflammation or PCSK9 local levels may have beneficial effects on EAT metabolism and cardiovascular
risk needs further investigations.
1. Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9), one
of the key regulators of the LDL receptor (LDLR), is a soluble
member of the mammalian proprotein convertase family of
secretory serine endoproteases [1]. While the liver is the
main contributor to circulating PCSK9, other tissues pro-
duce PCSK9 pointing out its possible role beyond LDLR
expression [2, 3]. PCSK9 seems to play a role in atheroscle-
rotic plaque development, i.e., it is expressed in endothelial
cells, regulates the migration ability of smooth muscle cells
[4], and is raised by shear stress [5]. Circulating platelets
have also been added to the list of PCSK9 targets [6], together
with the description of a proinflammatory effect on macro-
phages [7].
It is well-established that body fat accumulation leads to
metabolic diseases and increases cardiovascular (CV) risk
[8]. Among different fat depots, the visceral epicardial adipose
tissue (EAT) is an important risk factor for CV diseases
(CVD), from atherosclerosis to cardiac remodeling, heart fail-
ure, valve calcification, and stenosis [9–16]. Although in phys-
iological conditions, EAT nourishes the heart and plays
protective functions, e.g., mechanical protection of coronaries,
local energy store, and cryoprotection of the heart [17], when
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EAT volume expands, it becomes detrimental. These effects
are mainly due to the release of bioactive molecules that affect
the electrophysiological and contractile properties of cardio-
myocytes and that promote cardiac remodeling, fibrosis, and
coronary atherosclerosis progression [18]. Indeed, EAT lies
in continuity to the myocardium and shares the same micro-
circulation. Vasocrine and paracrine interactions of bioactive
molecules with coronary vessels and the myocardium exist.
EAT hypertrophy promotes adipocyte degeneration and
drives local inflammation through an increased infiltration
of immune cells [19–21]. In particular, a rise in EAT adipocyte
size has been associated with lipid droplet degeneration, the
presence of macrophages polarized toward a proinflammatory
M1 state, and the local expression of proinflammatory media-
tors [21]. Although EAT inflammation can increase, the levels
of mediators produced locally may not correlate with the
corresponding plasma levels [22].
EAT can be a proxy of overall visceral adiposity [23], and
since this latter represents a potential source of PCSK9 [22],
the present study is aimed at evaluating whether PCSK9 is
expressed in EAT and if a correlation with EAT amount
and local inflammation, regardless of total circulating levels,
can be found. PCSK9 may therefore be ascribed among those
bioactive molecules belonging to the EAT secretome affecting
vascular homeostasis and heart health.
2. Materials and Methods
2.1. Study Population. A total of 68 patients with coronary
artery disease (CAD) or valvular diseases (VR) and 46 con-
trol subjects matched for age, sex, and BMI (CTR) were
enrolled in the study. Patients were recruited at the IRCCS
Policlinico San Donato between October 2012 and July
2016. We followed the methods cited in our present paper
by Dozio et al. [24]. We excluded patients with the following
criteria: age ≤ 18 years, acute myocardial infarction in the
previous month, end-stage heart failure, other heart diseases
different from CAD and VR, malignant diseases, major
abdominal surgery in the previous six months, renal and liver
diseases, chronic inflammatory diseases, more than 3%
change in body weight in the previous three months, and
missing or incomplete clinical history and data. Among the
68 patients, 32 underwent open heart surgery. Twenty-one
required coronary artery bypass surgery (CABG), an elective
open heart procedure in hemodynamically stable patients
taking their standard cardiac treatments and under the care
of the cardiologist, and 11 required valve replacement. EAT
samples were collected just from these 32 patients during
surgery. Due to the lower amount of tissue isolated during
surgery, 22 samples were used for microarray studies and
10 samples for protein expression studies. Blood samples
for plasma quantification of PCSK9 were obtained from
the total of patients and CTR subjects. Written informed
consent was obtained from all participants. The study was
approved by the local ethics committee (ASL Milano Due,
protocol 2516) and conducted in accordance with the Decla-
ration of Helsinki, as revised in 2013, and Good Clinical
Practice guidelines.
2.2. Biochemical Parameters. Blood samples were collected
after overnight fasting, into pyrogen-free EDTA tubes or
in tubes for serum collection. EDTA plasma samples for
nonroutine assays were obtained after centrifugation at
1200 g for 15min and immediately stored at -20°C until sub-
sequent analyses. A cobas 6000 analyzer and commercial
kits (Roche Diagnostics, Milan, Italy) were used for the
quantification of routine biochemical parameters, as previ-
ously reported [24–27]. LDL-cholesterol was calculated with
the Friedewald formula. The homeostasis model assessment
of insulin resistance (HOMA-IR) was calculated using the
following equation: HOMA‐IR = ðfasting insulin ½μU/mL ×
fasting glucose ½mmol/LÞ/22:5.
2.3. Anthropometric Measures.Weight, height, and waist cir-
cumference (WC) were directly measured at hospital admis-
sion. Weight and height were recorded to the nearest 0.1 kg
and 0.5 cm using standard scales and stadiometers. WC was
measured using a flexible tape. Body mass index (BMI) and
waist-to-height ratio (WHtR) were then calculated as weight
(kg)/height2 (m2) andWC (cm)/height (cm), respectively. As
defined by WHO, patients were classified as normal weight
(BMI 18.5-24.9 kg/m2), overweight (BMI 25.0-29.9 kg/m2),
and obese (BMI ≥ 30:0 kg/m2).
2.4. EAT Thickness Measurement. All patients underwent
standard echocardiography using commercially available
equipment (Vingmed-System Five; General Electric, Horten,
Norway). Briefly, EAT was identified as the echo-free space
between the outer wall of the myocardium and the visceral
layer of the pericardium. EAT thickness was measured per-
pendicularly on the free wall of the right ventricle at the
end-systole in three cardiac cycles. The parasternal long-
axis view allowed for the most accurate measurement of
EAT on the right ventricle, with optimal cursor beam orien-
tation in each view. Maximum EAT thickness was measured
at the point on the free wall of the right ventricle along the
midline of the ultrasound beam, perpendicular to the aortic
annulus, used as the anatomical landmark for this view
[28]. The average value of three cardiac cycles was calculated
and used for analysis.
2.5. EAT Collection. Before starting cardiopulmonary bypass
pumping, a sample of EAT adjacent to the proximal right
coronary artery was harvested. For RNA and protein expres-
sion studies, EAT samples were stored in an Allprotect Tissue
Reagent (QIAGEN, Hilden, Germany) at -20°C.
2.6. RNA Extraction and Microarray Analysis. Total RNA
was extracted from tissue with the RNeasy Lipid Tissue
Kit according to the manufacturer’s procedure (QIAGEN).
RNA concentration was quantified by NanoDrop 2000
(Thermo Scientific, Wilmington, Germany), and RNA
integrity was assessed using the Agilent RNA 6000 Nano
Kit and the Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). Gene expression was analysed by a one-
color microarray platform (Agilent): 50 ng of total RNA
was labeled with Cy3 using the Agilent Low Input Quick
Amp Labeling Kit-1 color, according to the manufacturer’s
directions. cRNA was purified with the RNeasy Mini Kit
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(QIAGEN), and the amount and labeling efficiency were
measured with NanoDrop. For hybridization, we used an
Agilent Gene Expression Hybridization Kit and scanned
with the Agilent G2565CA Microarray Scanner System.
Data were processed using Agilent Feature Extraction Soft-
ware (10.7) with the single-color gene expression protocol,
and raw data were analyzed with ChipInspector Software
(Genomatix, Munich, Germany). In brief, raw data were
normalized on the single-probe level based on the array
mean intensities, and statistics were calculated based on
the SAM algorithm by Tusher et al. [29]. Fold changes were
calculated from normalized data.
2.7. PCKS9 Assays (ELISA). Circulating levels of PCKS9 were
measured on EDTA-plasma samples according to the manu-
facturer’s directions with the PCSK9 Quantikine ELISA Kit
(SPC900) from R&D Systems (Minneapolis, MN). The mean
minimum detectable dose was 0.096 ng/mL [30]. The maxi-
mum intra- and interassay coefficients of variation were
6.5% and 5.9%, respectively.
2.8. Western Blot. EAT samples of heart tissues were homog-
enized with TissueLyser II (QIAGEN) in an ice-cold RIPA
lysis buffer (50mM Tris-HCl, pH7.5, 150mM NaCl, 1mM
EDTA, 1mM EGTA, 1% Triton X-100, 0.1% SDS, 0.5%
Na-deoxycholate, and 50mM sodium fluoride) containing
1% protease inhibitor cocktail (Sigma-Aldrich, Milan, Italy).
The homogenate was kept on ice for 30min, centrifuged at
500 rpm for 10min at 4°C, and the resulting supernatant cen-
trifuged at 13,200 rpm for 15min at 4°C. Protein concentra-
tion was determined with the Quantum Protein Assay Kit,
based on a BCA reagent (EuroClone, Milan, Italy). Equal
amounts of protein samples (30μg) were suspended in a
Laemmli sample buffer and separated using 4-20% Mini-
PROTEAN TGX Stain-Free Gels and a Tris/Glycine/SDS
running buffer (Bio-Rad). The separated proteins were then
transferred from the gel to a nitrocellulose membrane using
the Trans-Blot Turbo Mini Nitrocellulose Transfer Packs
and the Trans-Blot Transfer System (Bio-Rad). The mem-
branes were blocked with 5% dry milk in Tris-buffered
saline/0.1% Tween 20 for 1 h at room temperature, and the
blots were then incubated overnight at 4°C with a diluted
solution of the primary anti-PCSK9 antibody (1 : 500)
(GeneTex, Alton Pkwy, Irvine, CA, USA). The subsequent
incubation with a secondary antibody conjugated with
peroxidase (1 : 5000) was performed at room temperature
for 2 h. Immunoreactivity was detected by a working solu-
tion (Clarity Western ECL Substrate, Bio-Rad) and the
ChemiDoc Touch System.
2.9. Statistical Analysis. Quantitative variables are expressed
as median and 25th-75th percentiles or mean ± SD. Qualita-
tive variables are summarized as numbers and percentages.
The normality of data distribution was assessed with the
Kolmogorov-Smirnoff test. Comparison between two groups
was performed by t-test or Mann-Whitney tests for contin-
uous variables. Fisher’s exact test was used for nominal var-
iables. Relations between parameters were examined with
the Spearman correlation test. Data were analyzed using
the GraphPad Prism 5.0 biochemical statistical package
(GraphPad Software, San Diego, CA). A p value < 0.05 was
considered significant.
3. Results
3.1. Patient Characteristics. The main demographic, anthro-
pometric, clinical, and biochemical characteristics of patients
are shown in Table 1. Mean age (± standard deviation, SD)
was 65:99 ± 10:64 years and males were the majority
(88.24%). According to the body mass index (BMI), roughly
50% were overweight and 30% obese. EAT thickness ranged
from 3 to 12mm (mean value ± SD: 7:40 ± 2:55mm). Relative
to lipid profile, this was in the normal range: total cholesterol
148:00 ± 27:74mg/dL, LDL-cholesterol (LDL-C) 79:96 ±
24:74mg/dL, and HDL-C 47:07 ± 26:65mg/dL. Sixty-seven
% (67.65%) were under statin treatment. Out of 68 patients,
48 had a diagnosis of coronary artery disease (CAD) and 11
of valve disease. Thirty-two underwent open heart surgery
for coronary bypass grafting (CABG, n = 21) or valvular
replacement (VR, n = 11). As shown in Table 1, patients in
this subgroup had a lower incidence of diabetes with lower
levels of HbA1c.
3.2. PCSK9 Expression in EAT. PCSK9 expression in EAT
was evaluated at both the gene and protein levels. PCSK9
gene expression was evaluated by microarray analysis
(mean expression level ± SD: 6:14 ± 4:57 arbitrary unit), with
the PCSK9 local level being positively correlated with EAT
thickness (r = 0:502, p = 0:017). Since statins increase the
PCSK9 levels, PCSK9 gene expression was evaluated in both
patients taking and patients not taking statins: no difference
has been observed between the two groups (p > 0:05) (data
not shown). The immunoreactive band of 62-66 kDa
confirmed the protein expression of PCSK9 (Figure 1).
3.3. Correlation of PCSK9 Expression with Genes Involved
in the Inflammatory Response in EAT. The expression of 142
genes (supplementary Table 1) involved in the inflammatory
response in EAT was analyzed and correlated with the PCSK9
levels. Twenty-two genes were found to be directly correlated
with PCSK9, especially those encoding for chemokines and
chemokine receptors, which exert chemotactic activity for
lymphocytes, monocytes, and granulocytes, and interleukins.
Names and functions of the genes which correlate with
PCSK9 are reported in Table 2.
3.4. Plasma Levels of PCSK9. Plasma levels of PCSK9 were
measured in CVD patients and in a group of 29 CTR. PCSK9
was higher in CVD patients than in CTR (293:90 ± 91:13 vs.
204:20 ± 64:61ng/mL, respectively; p < 0:0001) (Figure 2).
Among the CVD patients, circulating PCSK9 levels were
higher in those given statins (246:10 ± 84:72ng/mL vs.
309:20 ± 85:95ng/mL; p < 0:01). EAT thickness was also
higher in CVD patients than in CTR (7:40 ± 2:55mm vs.
3:79 ± 1:59ng/mL; p < 0:0001). Correlation analyses of the
plasma PCSK9 levels with PCSK9 expression in EAT and
EAT thickness were not statistically significant (p > 0:05).
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4. Discussion
In the present study, for the firt time, we have demonstrated
that EAT is a source of PCSK9 and that EAT inflammation is
associated with local PCSK9 expression, regardless of the cir-
culating PCSK9 levels.
The liaison between PCSK9 and adipose tissue still lacks
evidence. It was previously demonstrated that PCSK9 is
expressed and secreted by viscaral adipose tissue (VAT)
and correlated with BMI [31]. PCSK9 seems to reduce VAT
accumulation independently of the LDLR by promoting the
degradation of the very-low density lipoprotein receptor
(VLDLR) in adipocytes, thereby limiting fatty acid internali-
zation [32, 33]. PCSK9 R46L carriers, compared with noncar-
riers, have shown increased BMI, a rise in the percentage of
total and android fat masses, and a higher EAT thickness.
These observations were replicated by the same group in
PCSK9 KO mice, that showed an increment in visceral
adipose tissue, but not in the subcutaneous ones [32, 33].
Conversely, we observed positive correlations of PCSK9
expression in EAT with EAT amount and local inflamma-
tion, but not with the PCSK9 circulating levels. Overall,
inflammation may be the main link between EAT enlarge-
ment and PCSK9 expression. Indeed, our and other groups
found that in CVD patients, EAT is infiltrated by macro-
phages polarized toward a proinflammatory M1 state and
T- and B-lymphocytes and that the local inflammatory status
is strongly associated with EAT adipocyte size, EAT amount,
and lipid droplet degeneration [21, 34, 35]. Therefore, we can
Table 1: Demographic, anthropometric, clinical, and biochemical characteristics.
CVD (n = 68) CAGB+VR (n = 32)
Age (years) 65:99 ± 10:64, 66.00 (59.00-74.75) 66:31 ± 10:96, 68.50 (55.75-77.00)
Male gender (n, %) 60, 88.24% 28, 87.50%
BMI 28:50 ± 4:69, 27.80 (25.40-30.39) 28:07 ± 4:95, 26.00 (24.63-30.57)
WC (cm) 106:00 ± 13:97, 105.00 (102.00-116.00) 104:90 ± 12:28, 104.00 (102.00-110.80)
EAT thickness (mm) 7:40 ± 2:55, 8.00 (5.00-9.00) 6:70 ± 2:27, 7.00 (5.00-8.00)
Fasting glucose (mg/dL) 102:70 ± 40:22, 93.00 (81.75-107.00) 93:58 ± 15:76, 94.00 (79.00-103.00)
Fasting insulin (microU/mL) 9:51 ± 6:66, 8.15 (5.87-11.39) 9:24 ± 4:19, 8.68 (6.27-12.22)
HbA1c (%) 5:49 ± 1:33, 5.41 (4.93-6.04) 4:90 ± 1:09, 5.17 (4.06-5.76)∗
HOMA-IR 2:21 ± 1:88, 1.57 (1.12-2.71) 1:64 ± 0:73, 1.61 (1.02-2.23)
Total cholesterol (mg/dL) 157:20 ± 36:33, 154.50 (134.50-179.80) 161:80 ± 37:24, 159.50 (132.80-182.80)
LDL-cholesterol (mg/dL) 89:22 ± 32:39, 83.80 (68.20-108.70) 93:56 ± 35:06, 92.20 (65.20-115.00)
HDL-cholesterol (mg/dL) 54:54 ± 37:60, 43.00 (33.50-53.00) 70:97 ± 48:22, 48.00 (40.00-103.00)
Triglycerides (mg/dL) 119:90 ± 68:68, 105.50 (74.00-152.50) 98:58 ± 56:11, 97.00 (43.00-122.00)
CRP (mg/dL) 0:99 ± 1:92, 0.30 (0.10-0.80) 0:71 ± 1:32, 0.20 (0.10-0.50)
ALT (U/L) 34:66 ± 35:79, 25.00 (15.00-39.00) 33:74 ± 42:11, 24.00 (15.00-32.00)
AST (U/L) 30:82 ± 31:93, 21.00 (16.00-39.00) 35:35 ± 41:39, 21.00 (16.00-31.00)
Smoking (n, %) 38, 55.88% 15, 46.88%
Hypertension (n, %) 53, 77.94% 25, 78.13%
History of cardiovascular diseases (n, %) 25, 36.76% 11, 34.38%
Dyslipidemia (n, %) 46, 67.65% 18, 56.25%
Diabetes (n, %) 17, 25.00% 2, 6.25%∗
Aspirin (n, %) 48, 70.59% 20, 62.50%
ACEI/ARB (n, %) 46, 67.64% 23, 71.88%
Antidiabetic agents 15, 22.07% 2, 6.25%
β-Blockers (n, %) 39, 57.35% 16, 50.00%
Calcium channel blockers (n, %) 15, 22.06% 6, 18.75%
Statins (n, %) 46, 67.65% 18, 56.25%
The table shows the main characteristics of the whole studied population (CVD: cardiovascular disease patients) and the subgroup of patients who underwent
either CABG (coronary artery bypass grafting) or VR (valvular replacement). Data are expressed asmean ± standard deviation, median (25th-75th percentiles)
or number and proportions. ACEI: angiotensinogen-converting enzyme inhibitor; ALT: alanine aminotransferase; AST: aspartate aminotransferase; ARB:
angiotensin receptor blockade; BMI: body mass index; CRP: C reactive protein; EAT: epicardial adipose tissue; HbA1c: glycated hemoglobin; HOMA-IR:
homeostatic model assessment of insulin resistance; WC: waist circumference. ∗p < 0:05.
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Figure 1: PCSK9 expression in Epicardial adipose tissue (EAT).
Western blot analysis shows PCSK9 expression in EAT samples.
4 Mediators of Inflammation
hypothesize that EAT inflammation may upregulate PCSK9
expression which in turn can exert proinflammatory and det-
rimental effects locally and on tissues lying in contiguity
with EAT, such as the myocardium and coronary vessels.
The bidirectional association between inflammation and
PCSK9 has been previously demonstrated both in vitro
and in the animal models [4, 36]. PCSK9 silencing in mac-
rophages can partially reduce oxLDL-induced-cytokine
production, with PCSK9 KOmice showing a reduced inflam-
matory response [37]. PCSK9 stimulates the expression of
proinflammatory cytokines after exposure to LPS, and
PCSK9 downregulation in atherosclerotic plaques reduces
macrophage infiltration and cytokine secretion [7, 37–39].
Although our study did not explore the mechanisms linking
inflammation to PCSK9 expression, it confirmed the exis-
tence of correlations also in EAT. Looking at the molecules
associated with PCSK9 expression, it can be noted that they
are mainly chemokines, cytokines, and other molecules
involved in chemotaxis, differentiation, and activation of dif-
ferent leukocyte populations as well as proinflammatory
Table 2: Correlation analyses of PCSK9 with genes involved in the inflammatory response in EAT.
Genes Family group Function
Correlation
coefficient,
p value
C5 Regulation of inflammation
Member of the complement system: mediator of local
inflammatory process
0.446, 0.038
CCL11 Chemokine Chemotactic activity for eosinophils 0.508, 0.016
CCL20 Chemokine Chemotactic activity for lymphocytes 0.470, 0.028
CCL21 Chemokine
Chemotactic for thymocytes and activated T-cells, but not for B-cells,
macrophages, or neutrophils
-0.447, 0.037
CCR6 Chemokine receptor Ligand for macrophage inflammatory protein 3 alpha 0.416, 0.050
CEBPB Regulation of inflammation
Transcription factor regulating the expression of genes involved in immune
and inflammatory responses
0.433, 0.044
CSF3 Regulation of inflammation It control of production, differentiation, and function of granulocytes 0.423, 0.049
CXCL2 Regulation of inflammation
Produced by activated monocytes and neutrophils and expressed at sites of
inflammation and may suppress progenitor cell proliferation
0.459, 0.032
CXCL6 Regulation of inflammation Chemotactic for neutrophil granulocytes 0.459, 0.031
CXCL10 Regulation of inflammation
Proinflammatory cytokine that is involved in a wide variety of processes such as
chemotaxis, differentiation, and activation of peripheral immune cells, regulation
of cell growth, apoptosis, and modulation of angiostatic effects
0.456, 0.033
CXCL13 Regulation of inflammation Chemotactic for B-lymphocytes 0.591, 0.004
CXCR5 Regulation of inflammation Binds to B-lymphocyte chemoattractant (BLC) and is involved in B-cell migration 0.431, 0.045
FASLG Other molecules
Immune system regulation, including activation-induced cell death of T-cells and
cytotoxic T lymphocyte-induced cell death
0.634, 0.002
IFNγ Other molecules Potent activator of macrophages 0.443, 0.039
IL1β Interleukins
Induces prostaglandin synthesis, neutrophil influx and activation, T-cell activation
and cytokine production, and B-cell activation
0.445, 0.038
IL10 Interleukins
Major immune regulatory cytokine that acts on many cells of the immune system
where it has profound anti-inflammatory functions, limiting excessive tissue
disruption caused by inflammation
0.421, 0.050
IL17A Interleukins Proinflammatory cytokine produced by activated T-cells 0.476, 0.025
IL17F Interleukins
Expressed by activated T-cells and has been shown to stimulate the production
of several other cytokines, including IL6, IL8, and CSF2/GM_CSF
0.499, 0.018
IL33 Interleukins
Acts as a chemoattractant for Th2 cells and may function as an “alarmin,” that
amplifies immune responses during tissue injury
-0.429, 0.046
KNG1 Other molecules Mediator of inflammation 0.439, 0.041
RIPK4 Regulation of inflammation Activator of NF-kappa-B 0.572, 0.005
TLR9 Regulation of inflammation
TLR9 is a nucleotide-sensing TLR which is activated by unmethylated cytidine-
phosphate-guanosine (CpG) dinucleotides. Acts via MYD88 and TRAF6, leading
to NF-kappa-B activation, cytokine secretion, and the inflammatory response
0.431, 0.046
TLR10 Regulation of inflammation
Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion,
and the inflammatory response
0.484, 0.027
TNFSF9 Other molecules Induces the proliferation of activated peripheral blood T-cells 0.435, 0.043
The table reports correlations of PCSK9 level with genes involved in the inflammatory response in EAT. Spearman’s correlation coefficients and corresponding
p values are reported.
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mediators that can amplify local inflammation through
NF-κB activation. In particular, the association previously
observed in vitro between PCSK9 and CXCL2 [7] has been
detected in EAT too, thus confirming that PCSK9 can play
a role in monocyte recruitment.
The protein expression of PCSK9 in EAT argues that
PCSK9 is part of the EAT secretome. Therefore, in addition
to increasing local EAT inflammation, PCSK9 derived from
EATmay directly affect the coronary vessels and the myocar-
dium, thus increasing CV risk. This amount of EAT-secreted
PCSK9 is added to the amount that can be derived from the
circulation. The finding that CVD patients have higher
plasma PCSK9 levels is in line with previous reports showing
PCSK9 to be associated with the Framingham Risk Score [40]
or with inflammation in the acute phase and hypercholester-
olemia in patients with acute coronary syndrome [41]. In our
study, we did not find any association of plasma PCSK9 with
local EAT expression and inflammation. Therefore, EAT-
derived PCSK9 may play an additional and independent risk
to CVD. Recently, it has also been demonstrated that PCSK9
is not only implicated in atherogenesis but can also deter-
mine the development of infarct size and affect contractive
function of cardiomyocytes [5, 42].
From a clinical point of view, in atherosclerotic plaques,
PCSK9 monoclonal antibodies can reduce macrophage con-
tent through the reduction of CCR2 expression in mono-
cytes with a consequent impairment in their migratory
capacity [43, 44]. Whether this treatment may affect EAT
inflammation, its metabolism, and amount is unknown;
therefore, additional studies are necessary to demonstrate
any potential effect of reduced PCSK9 levels on EAT and
EAT-associated CV risk.
It is important to point out that about 50% of our patients
were under statin therapy. Statin use is associated with a
reduction in EAT thickness and inflammation, supporting
the hypothesis of a direct action of statins on the EAT secre-
tory profile [45, 46]. Targeting some inflammatory media-
tors, such as IL1β, reduces CV events, regardless of LDL-C
lowering [47]. Differently, statins may upregulate the expres-
sion of PCSK9 via SREBP-2 [48]. Therefore, the PCSK9
levels in EAT may be influenced by the direct effect of statins
on its expression and the modulation of local inflammation
too. Notably, no rise in PCSK9 protein expression was found
in EAT from patients taking statins. However, no data are
available relative to the association between modulation of
EAT inflammation and PCSK9 levels.
Our study has some limitations. First, the amount of EAT
collected during surgery did not allow us to evaluate EAT
transcriptomes and proteomes on the same samples. Second,
we did not have a surgical control group used to compare
PCSK9 and the other genes analyzed. Third, our study group
is composed of both CABG and VR patients. Although the
mechanisms driving the two pathologies are different, many
studies demonstrated the involvement of EAT amount and
secretome in the progression of both diseases [14, 49–52].
Fourth, since our study is cross-sectional, our findings cannot
imply causality. In conclusion, we provided evidence for the
possible role of PCSK9 as an EAT-derived risk factor for
CVD. In the clinical setting, reducing both the EAT inflam-
mation and the PCSK9 local levels might have beneficial
effect on EAT metabolism and EAT-related CV risk, but this
needs further investigations.
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